Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology.

Baglietto-Vargas D, Medeiros R, Martinez-Coria H, LaFerla FM, Green KN.

Biol Psychiatry. 2013 Sep 1;74(5):357-66. doi: 10.1016/j.biopsych.2012.12.003. Epub 2013 Jan 8.

2.

L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease.

Peng Y, Sun J, Hon S, Nylander AN, Xia W, Feng Y, Wang X, Lemere CA.

J Neurosci. 2010 Jun 16;30(24):8180-9. doi: 10.1523/JNEUROSCI.0340-10.2010.

3.

FLZ alleviates the memory deficits in transgenic mouse model of Alzheimer's disease via decreasing beta-amyloid production and tau hyperphosphorylation.

Bao XQ, Li N, Wang T, Kong XC, Tai WJ, Sun H, Zhang D.

PLoS One. 2013 Nov 4;8(11):e78033. doi: 10.1371/journal.pone.0078033. eCollection 2013.

4.

Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.

Rockenstein E, Torrance M, Mante M, Adame A, Paulino A, Rose JB, Crews L, Moessler H, Masliah E.

J Neurosci Res. 2006 May 15;83(7):1252-61.

PMID:
16511867
5.

Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease.

Manczak M, Reddy PH.

Hum Mol Genet. 2012 Dec 1;21(23):5131-46. doi: 10.1093/hmg/dds360. Epub 2012 Aug 27.

6.

Fyn knock-down increases Aβ, decreases phospho-tau, and worsens spatial learning in 3×Tg-AD mice.

Minami SS, Clifford TG, Hoe HS, Matsuoka Y, Rebeck GW.

Neurobiol Aging. 2012 Apr;33(4):825.e15-24. doi: 10.1016/j.neurobiolaging.2011.05.014. Epub 2011 Jul 7.

7.

[Alzheimer disease: cellular and molecular aspects].

Octave JN.

Bull Mem Acad R Med Belg. 2005;160(10-12):445-9; discussion 450-1. French.

PMID:
16768248
8.

Intraneuronal APP, not free Aβ peptides in 3xTg-AD mice: implications for tau versus Aβ-mediated Alzheimer neurodegeneration.

Winton MJ, Lee EB, Sun E, Wong MM, Leight S, Zhang B, Trojanowski JQ, Lee VM.

J Neurosci. 2011 May 25;31(21):7691-9. doi: 10.1523/JNEUROSCI.6637-10.2011. Retraction in: J Neurosci. 2015 Feb 25;35(8):3724.

9.

APP/PS1 mice overexpressing SREBP-2 exhibit combined Aβ accumulation and tau pathology underlying Alzheimer's disease.

Barbero-Camps E, Fernández A, Martínez L, Fernández-Checa JC, Colell A.

Hum Mol Genet. 2013 Sep 1;22(17):3460-76. doi: 10.1093/hmg/ddt201. Epub 2013 May 6.

10.

Involvement of WAVE accumulation in Abeta/APP pathology-dependent tangle modification in Alzheimer's disease.

Takata K, Kitamura Y, Nakata Y, Matsuoka Y, Tomimoto H, Taniguchi T, Shimohama S.

Am J Pathol. 2009 Jul;175(1):17-24. doi: 10.2353/ajpath.2009.080908. Epub 2009 Jun 4.

11.

Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model.

Hirata-Fukae C, Li HF, Hoe HS, Gray AJ, Minami SS, Hamada K, Niikura T, Hua F, Tsukagoshi-Nagai H, Horikoshi-Sakuraba Y, Mughal M, Rebeck GW, LaFerla FM, Mattson MP, Iwata N, Saido TC, Klein WL, Duff KE, Aisen PS, Matsuoka Y.

Brain Res. 2008 Jun 24;1216:92-103. doi: 10.1016/j.brainres.2008.03.079. Epub 2008 Apr 10.

PMID:
18486110
13.

Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.

Chu J, Lauretti E, Craige CP, Praticò D.

J Alzheimers Dis. 2014;41(3):729-37. doi: 10.3233/JAD-140105.

PMID:
24662099
14.

Baicalein reduces β-amyloid and promotes nonamyloidogenic amyloid precursor protein processing in an Alzheimer's disease transgenic mouse model.

Zhang SQ, Obregon D, Ehrhart J, Deng J, Tian J, Hou H, Giunta B, Sawmiller D, Tan J.

J Neurosci Res. 2013 Sep;91(9):1239-46. doi: 10.1002/jnr.23244. Epub 2013 May 17.

15.

It may take more than a shot: alternatives to immunotherapy for Alzheimer's disease.

O'Banion MK.

Biol Psychiatry. 2013 Sep 1;74(5):316-7. doi: 10.1016/j.biopsych.2013.07.003. No abstract available.

PMID:
23932341
16.

Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease.

Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM.

J Neurosci. 2006 Aug 30;26(35):9047-56.

17.

Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of AD.

Kitazawa M, Cheng D, Laferla FM.

J Neurochem. 2009 Mar;108(6):1550-60. doi: 10.1111/j.1471-4159.2009.05901.x. Epub 2009 Jan 22.

18.

Insulin receptor signaling mediates APP processing and β-amyloid accumulation without altering survival in a transgenic mouse model of Alzheimer's disease.

Stöhr O, Schilbach K, Moll L, Hettich MM, Freude S, Wunderlich FT, Ernst M, Zemva J, Brüning JC, Krone W, Udelhoven M, Schubert M.

Age (Dordr). 2013 Feb;35(1):83-101. doi: 10.1007/s11357-011-9333-2. Epub 2011 Nov 6.

19.

CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease.

Caccamo A, Maldonado MA, Bokov AF, Majumder S, Oddo S.

Proc Natl Acad Sci U S A. 2010 Dec 28;107(52):22687-92. doi: 10.1073/pnas.1012851108. Epub 2010 Dec 13.

20.

Xanthoceraside rescues learning and memory deficits through attenuating beta-amyloid deposition and tau hyperphosphorylation in APP mice.

Jin G, Wang LH, Ji XF, Chi TY, Qi Y, Jiao Q, Xu Q, Zhou XY, Zhang R, Zou LB.

Neurosci Lett. 2014 Jun 24;573:58-63. doi: 10.1016/j.neulet.2014.04.032. Epub 2014 May 5.

PMID:
24810883
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk